A detailed history of Segall Bryant & Hamill, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 41,366 shares of ABBV stock, worth $7.57 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
41,366
Holding current value
$7.57 Million
% of portfolio
0.11%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$163.84 - $199.33 $6.78 Million - $8.25 Million
41,366 New
41,366 $8.17 Million
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $147,483 - $170,733
-1,104 Reduced 0.7%
157,600 $23.5 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $510,958 - $635,854
-3,856 Reduced 2.37%
158,704 $21.4 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $161,673 - $186,191
-1,118 Reduced 0.68%
162,560 $25.9 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $22.6 Million - $27.1 Million
163,678 New
163,678 $26.5 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $22.5 Million - $25.9 Million
167,978 New
167,978 $22.5 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $7,844 - $9,972
-57 Reduced 0.03%
169,179 $25.9 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $546,529 - $678,088
-4,141 Reduced 2.39%
169,236 $27.4 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $436,488 - $552,283
-4,063 Reduced 2.29%
173,377 $23.5 Million
Q3 2021

Nov 03, 2021

BUY
$106.4 - $120.78 $122,998 - $139,621
1,156 Added 0.66%
177,440 $19.1 Million
Q2 2021

Aug 12, 2021

SELL
$105.21 - $117.21 $10,205 - $11,369
-97 Reduced 0.05%
176,284 $19.9 Million
Q1 2021

May 13, 2021

SELL
$102.3 - $112.62 $978,806 - $1.08 Million
-9,568 Reduced 5.15%
176,381 $19.1 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $557,554 - $752,757
-6,927 Reduced 3.59%
185,949 $19.9 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $1.14 Million - $1.33 Million
-13,231 Reduced 6.42%
192,876 $16.9 Million
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $161,927 - $216,683
-2,207 Reduced 1.06%
206,107 $20.2 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $734,268 - $1.11 Million
-11,384 Reduced 5.18%
208,314 $15.9 Million
Q4 2019

Feb 11, 2020

SELL
$72.13 - $90.25 $803,528 - $1.01 Million
-11,140 Reduced 4.83%
219,698 $19.5 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $533,062 - $640,894
-8,464 Reduced 3.54%
230,838 $17.5 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $1.07 Million - $1.37 Million
-16,257 Reduced 6.36%
239,302 $0
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $386,394 - $454,767
-5,009 Reduced 1.92%
255,559 $0
Q4 2018

Feb 15, 2019

BUY
$77.85 - $96.01 $151,496 - $186,835
1,946 Added 0.75%
260,568 $24 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $1 Million - $1.11 Million
-11,265 Reduced 4.17%
258,622 $0
Q2 2018

Aug 08, 2018

BUY
$89.78 - $106.23 $8.45 Million - $10 Million
94,168 Added 53.59%
269,887 $0
Q1 2018

May 16, 2018

SELL
$92.01 - $123.21 $263,976 - $353,489
-2,869 Reduced 1.61%
175,719 $0
Q4 2017

Feb 15, 2018

SELL
$89.56 - $98.21 $1.4 Million - $1.54 Million
-15,647 Reduced 8.06%
178,588 $0
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $13.6 Million - $17.3 Million
194,235
194,235 $0

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.